{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-012442","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2024-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.081617+00:00","generated_at":"2026-06-03T18:54:24.759385+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pieris Pharmaceuticals announces 1-for-80 reverse stock split to regain Nasdaq compliance","bullets":["Reverse stock split at ratio 1-for-80 effective 5:00 pm ET on April 22, 2024; begins trading split-adjusted on April 23 under symbol PIRS.","Outstanding shares reduced from 98,935,025 to approximately 1,236,688; authorized common shares decreased from 300M to 3.75M.","Split aims to raise bid price above $1.00 per share and meet Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement.","No fractional shares issued; fractional interests rounded up to one whole share. CUSIP changes to 720795202.","All outstanding options, warrants, and preferred stock conversion terms adjusted proportionately per their governing documents."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-012442","json":"https://secwatch.observer/filing/0001437749-24-012442.json","markdown":"https://secwatch.observer/filing/0001437749-24-012442.md","text":"https://secwatch.observer/filing/0001437749-24-012442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000143774924012442/0001437749-24-012442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000143774924012442/pirs20240401_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T18:54:24.759385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6aa807884790bbb3ac8d7059eb29288db79c83d6","claim":"PALVELLA THERAPEUTICS, INC.: Filing of Certificate of Change to effect a 1-for-80 reverse stock split of common stock and adjust authorized shares accordingly (effective 2024-04-22).","evidence_excerpt":"The Company effected the Reverse Stock Split pursuant to the Company’s filing of a Certificate of Change (the “Certificate”) with the Nevada Secretary of State on April 18, 2024, in accordance with Nevada Revised Statutes (“ NRS ”) 78.209.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000143774924012442/0001437749-24-012442-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-04-22"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}